Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 1/20 | 0.60 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | CALML3 | P27482 | 6/20 | 0.48 |
| ▸ | GRM2 | Q14416 | 6/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5618573 | 1.00 | F10 (0.60) | F10MAOAMAOBCALML3GRM2 | |
| SCHEMBL5618569 | 1.00 | F10 (0.60) | F10MAOAMAOBCALML3GRM2 | |
| SCHEMBL7308961 | 0.88 | MAOA (0.51) | F10MAOAMAOBCALML3GRM2 | |
| SCHEMBL7308967 | 0.88 | MAOA (0.51) | F10MAOAMAOBCALML3GRM2 | |
| SCHEMBL5617802 | 0.83 | F10 (0.54) | F10MAOAGRM2SIGMAR1 | |
| SCHEMBL5617800 | 0.83 | F10 (0.54) | F10MAOAGRM2SIGMAR1 | |
| SCHEMBL7304715 | 0.83 | F10 (0.54) | F10MAOAGRM2SIGMAR1 | |
| SCHEMBL5617834 | 0.83 | F10 (0.54) | F10MAOAGRM2SIGMAR1 | |
| SCHEMBL7304721 | 0.83 | F10 (0.54) | F10MAOAGRM2SIGMAR1 | |
| SCHEMBL10162810 | 0.82 | MAOB (0.48) | F10MAOAMAOBCALML3GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0657440-B1 | Oxazolidine-2-one derivatives as MAO inhibitors | HOFFMANN LA ROCHE (CH) | 2000-04-05 | — | — | EP | disclosed |
| US-5574055-A | COGNITIVE AND NEURODEGENERATIVE DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1996-11-12 | — | — | US | disclosed |
| EP-0657440-A1 | Oxazolidine-2-one derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1995-06-14 | — | — | EP | disclosed |